Baocheng C. Wang
Jinan, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: November 11, 2025
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial.
Journal: JAMA oncology
Published: November 14, 2024
Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer.
Journal: Scientific reports
Published: August 12, 2024
Histological sarcomatoid transformation in a lung adenocarcinoma patient following immune checkpoint blockade.
Journal: Therapeutic advances in medical oncology
Published: October 14, 2023
Effectiveness and safety of human type 5 recombinant adenovirus (H101) in malignant tumor with malignant pleural effusion and ascites: A multicenter, observational, real-world study.
Journal: Thoracic cancer
Published: July 07, 2023
Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations.
Journal: Therapeutic advances in medical oncology
Published: December 09, 2022
Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience.
Journal: Frontiers in cardiovascular medicine
Published: November 16, 2022
Impact of endogenous glucocorticoid on response to immune checkpoint blockade in patients with advanced cancer.
Journal: Frontiers in immunology
Published: October 27, 2022
An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870).
Journal: Therapeutic advances in medical oncology
Published: June 21, 2022
Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2020 Version)
Journal: Zhongguo fei ai za zhi = Chinese journal of lung cancer
Published: April 25, 2021
Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 20, 2020
Last Updated: 09/26/2026